Elanco's acquisition of Bayer's animal health business not opposed

THE Australian Competition & Consumer Commission (ACCC) will not oppose Elanco’s acquisition of Bayer AG’s animal health business, after Elanco provided a court-enforceable undertaking to divest four animal parasite treatment brands.

Bayer and Elanco are close to sealing to major deal covering a range of animal health products. Image Mark Saunders.

09 July 2020
comments
share

The ACCC had concerns about the effect of the acquisition in the markets for sheep lice treatments, and worming treatments for cats and dogs.

Independent information for agriculture

Delivering high value research and information on best practices to help improve farming productivity, efficiency and profitability.

Individual Membership (with print)

From $475 per year *(excluding GST)

SELECT PACKAGE

Print magazine plus full access to FarmingAhead.com.au
12 research reports per year used by farmers as purchasing decision references
Access valuable information on cropping machinery and technology specialisation
Read about livestock production, equipment evaluations and operational efficiency
Unlimited access to an extensive research archive
Consult with our on-site engineers & research staff
Member exclusive - present your views to help us drive our annual research topics

Try FarmingAhead.com.au for 30 days for ONLY $1

Best value

Corporate Membership

From $1,065 per year *(excluding GST)

SELECT PACKAGE

Print magazine plus full access to FarmingAhead.com.au for up to 3 users
12 research reports per year used by farmers as purchasing decision references
Access valuable information on cropping machinery and technology specialisation
Read about livestock production, equipment evaluations and operational efficiency
Unlimited access to an extensive research archive
Include your company's logo and web address in Farming Ahead magazine (1 issue)
Member exclusive - present your views to help us drive our annual research topics